Stay updated on Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.

Latest updates to the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed information about a clinical trial for Cabozantinib plus Durvalumab in bladder carcinoma, while adding a new revision number and the term 'Bladder Carcinoma'.SummaryDifference34%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.8%
Stay in the know with updates to Cabozantinib and Durvalumab Immuno-oncology Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.